Immune checkpoint expression in <scp>HNSCC</scp> patients before and after definitive chemoradiotherapy

Doescher, Johannes; Minkenberg, P; Laban, Simon; Kostezka, Ulrike; Witzleben, Adrian von; Hoffmann, Thomas; Schuler, Patrick J.; Weissinger, Stephanie E.

doi:10.1002/hed.26534

Cited by 16 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Assessment of the PD-L1 status revealed that all patients with recurrences had a negative CPS. This finding is in accordance with our previously published paper, where we could show that PD-L1 expression is a protection against the occurrence of recurrences [ 19 ].…”

Section: Discussionsupporting

confidence: 94%

Protein-Based Oncopanel as Addition to Target Sequencing in Head and Neck Squamous Cell Carcinoma to Individualize Treatment Decisions

Witzleben

Müller‐Richter

Maurus

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of cancers and patients have limited therapy options if primary treatment fails. Therefore, additional information about the biology of the tumor is essential. Here we performed a feasibility study of concurrently applying two precision diagnostic tools in a consecutive series of HNSCC patients. We analyzed tumor samples of 31 patients using a genomic (oncomine) and a proteomic, immunohistochemical approach (oncopanel) and compared the result, also in the focus on their overlapping therapeutical targets. We found no strong correlation between the two approaches and observed a higher proportion of marker expression for the immunohistochemical panel. However, both panels show in our HNSCC cohort distinct patterns with druggable targets. The data suggest that both approaches complement one another and can be applied side-by-side to identify the best targets for the development of individual treatment options for HNSCC patients.

show abstract

Section: Discussionsupporting

confidence: 94%

Protein-Based Oncopanel as Addition to Target Sequencing in Head and Neck Squamous Cell Carcinoma to Individualize Treatment Decisions

Witzleben

Müller‐Richter

Maurus

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…CD3E is expressed specifically on T cells and high expression could be linked to a favorable prognosis (35). In an earlier study on a slightly different cohort, we were already able to show a loss of expression of CD27, which is expressed on T cells and is a co-stimulatory molecule, on protein level (36). This supports the observation made here of a downregulation of these two genes in poor responder under therapy.…”

Section: Discussionsupporting

confidence: 87%

Changes in Gene Expression Patterns in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Under Chemoradiotherapy Depend on Response

Doescher

Witzleben²,

Boukas

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Chemoradiotherapy (CRT) is a standard treatment for advanced head and neck squamous cell carcinoma (HNSCC). Unfortunately, not all patients respond to this therapy and require further treatment, either salvage surgery or palliative therapy. The addition of immunotherapy to CRT is currently being investigated and early results describe a mixed response. Therefore, it is important to understand the impact of CRT on the tumor microenvironment (TME) to be able to interpret the results of the clinical trials. Paired biopsies from 30 HNSCC patients were collected before and three months after completion of primary CRT and interrogated for the expression of 1392 immune- and cancer-related genes. There was a relevant difference in the number of differentially expressed genes between the total cohort and patients with residual disease. Genes involved in T cell activation showed significantly reduced expression in these tumors after therapy. Furthermore, gene enrichment for several T cell subsets confirmed this observation. The analysis of tissue resident memory T cells (TRM) did not show a clear association with impaired response to therapy. CRT seems to lead to a loss of T cells in patients with incomplete response that needs to be reversed. It is not clear whether the addition of anti-PD-1 antibodies alone to CRT can prevent treatment failure, as no upregulation of the targets was measurable in the TME.

show abstract

“…Since the classical approaches for identifying prognostic indicators in HNSCC, such as CT and MRI, no longer satisfy the clinical requirements for precision medicine ( 14 ), identification of novel prognostic markers and stratification of patients based on prognosis are warranted to provide new indicators for individualized precision treatment ( 15 ). On this premise, this study established CD27 expression as a potentially significant prognostic indicator in patients with HNSCC.…”

Section: Discussionmentioning

confidence: 99%

Constrast-enhanced computed tomography radiomics predicts CD27 expression and clinical prognosis in head and neck squamous cell carcinoma

Wang

Zhang²,

Wang³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

ObjectiveThis study aimed to construct a radiomics model that predicts the expression level of CD27 in patients with head and neck squamous cell carcinoma (HNSCC).Materials and methodsGenomic data and contrast-enhanced computed tomography (CT) images of patients with HNSCC were downloaded from the Cancer Genome Atlas and Cancer Imaging Archive for prognosis analysis, image feature extraction, and model construction. We explored the potential molecular mechanisms underlying CD27 expression and its relationship with the immune microenvironment and predicted CD27 mRNA expression in HNSCC tissues. Using non-invasive, CT-based radiomics technology, we generated a radiomics model and evaluated its correlation with the related genes and HNSCC prognosis.Results and conclusionThe expression level of CD27 in HNSCC may significantly influence the prognosis of patients with HNSCC. Radiomics based on contrast-enhanced CT is potentially effective in predicting the expression level of CD27.

show abstract

Immune checkpoint expression in HNSCC patients before and after definitive chemoradiotherapy

Cited by 16 publications

References 38 publications

Protein-Based Oncopanel as Addition to Target Sequencing in Head and Neck Squamous Cell Carcinoma to Individualize Treatment Decisions

Protein-Based Oncopanel as Addition to Target Sequencing in Head and Neck Squamous Cell Carcinoma to Individualize Treatment Decisions

Changes in Gene Expression Patterns in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Under Chemoradiotherapy Depend on Response

Constrast-enhanced computed tomography radiomics predicts CD27 expression and clinical prognosis in head and neck squamous cell carcinoma

Contact Info

Product

Resources

About